Home/Kamari Pharma/Liora Braiman, PhD

LB

Liora Braiman, PhD

Chief Scientific Officer

Therapeutic Areas

Dermatology Rare Diseases

Kamari Pharma Pipeline

Drug	Indication	Phase
KM-001	Palmoplantar Keratoderma, Olmsted Syndrome, Ichthyosis	Phase 1
KM-023	Severe Keratoderma and Ichthyosis	Preclinical

Leadership Team at Kamari Pharma

David Aviezer, PhD, MBA

Asaf Yarkoni, CPA

Chief Financial Officer

Dayana Michel, MD

SVP Medical and Clinical Affairs

View full Kamari Pharma profile